In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs Further prospective studies req'd? BEL remains an option for non-renal SLE tx. #ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk